On June 4, Novo Nordisk rose 3.12% in regular trading, trading at $44.05/share, with trading volume of $146 million. The stock rebounded following two consecutive trading days of pullback, supported by broad pharmaceutical sector strength and multiple company-specific catalysts.

On the news front, the pharmaceutical sector rallied broadly, with Merck up 4.33%, Eli Lilly up 4.05%, Bristol-Myers Squibb up 3.46%, Pfizer up 2.07%, and Johnson & Johnson up 1.92%, providing a favorable backdrop for Novo Nordisk's recovery. Additionally, multiple positive developments continued to build momentum: Novo Nordisk and its partner announced that the UAE will become the first market outside the United States to receive the oral version of Wegovy, with clinical trials demonstrating an average weight loss of 17% over 64 weeks. Furthermore, India has approved Wegovy for adolescents aged 12 and above weighing over 60 kilograms, expanding the drug's addressable patient population in a major emerging market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)